| P/E (FY) | — | Sales (TTM) | $238.1M |
| Earnings (TTM) | -$31.5M | ROE | −13.49% |
| Net Margin | −6.97% | ROIC | — |
| Debt / Equity | 0.38 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 17.57% |
Axogen, Inc. develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. Its products include the Avance Nerve Graft, a processed nerve allograft for surgical repair of peripheral nerve discontinuities; the Axoguard Nerve Connector, Protector, HA+ Protector, and Nerve Cap for aligning, protecting, and wrapping nerves; and the Avive+ Soft Tissue Matrix amniotic membrane allograft. It also offers the Avance Method for processing nerve grafts from donated human nerve tissue.
| Market Cap | $2.19B | Trading Days | 5292 |
| 52W High | 46.95 |
| 52W Low | 12.39 |
| % Off High | −12.35% |
| YTD | 25.73% | 1Y | 216.78% |
| 3Y | 383.55% | 5Y | 105.13% |
| 10Y | 512.35% | Since incept. (ann.) | 19.26% |
US 99% · Non Us 1%
| Ann. Volatility (1Y) | 54.13% | Ann. Volatility (3Y) | 65.25% |
| Sharpe (1Y) | 2.43 | Sharpe (3Y) | 1.15 |
| Max Drawdown (1Y) | −19.30% | Max Drawdown (3Y) | −58.22% |
| Beta (3Y, vs SPY) | 2.25 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TMDX | TransMedics Group, Inc. | $2.64B | 15.7 |
| BLFS | BIOLIFE SOLUTIONS INC | $1.56B | — |
| ITGR | Integer Holdings Corp | $3.41B | 34.7 |
| CNMD | CONMED Corp | $1.36B | 29.3 |
| LIVN | LivaNova PLC | $4.51B | — |
| CBLL | Ceribell, Inc. | $676.5M | — |
| CV | CapsoVision, Inc | $330.8M | — |
| ELMD | Electromed, Inc. | $326.9M | 46.4 |
| STXS | Stereotaxis, Inc. | $125.1M | — |
| VANI | Vivani Medical, Inc. | $113.0M | — |
| OM | Outset Medical, Inc. | $87.5M | — |
| NRXS | Neuraxis, INC |
| $80.9M |
| — |
